Anavex Life Sciences Corp (AVXL)

[nidan7500]

Thanks again bear. https://www.nature.com/articles/s41392-019-0063-8

Sigma-1 receptor ligands can enhance acetylcholine secretion.419,420 The sigma-1 receptor activator Anavex 2–73 has entered a phase III clinical trial after it was granted fast-track status by the FDA because of the promising results in phase II. The sigma-1 receptor is located in the mitochondrion-associated ER membrane so that the activation of the sigma-1 receptor can prolong Ca2+ signaling in mitochondria.421 Consequently, the local and specific elevation of [Ca2+] in the mitochondrial matrix can enhance ATP synthesis,422,423 which ameliorates hypometabolism."

"The most interesting and challenging phenomena regarding fluoxetine is that fluoxetine is clinically more effective in women than in men440 and that the prevalence of AD and other dementias is higher in women than in men441; meanwhile, women live significantly longer than men.442 These phenomena suggest that there are interplays or trade-offs between AD and longevity. In particular,

I find it hard to believe this is an entry error. If A2-73 has been fast tracked then we will see some kind of PR. Also note the part where a women's clinical benefit is mentioned. Wonder if this relates in any way to the work which Biostockclub has mentioned here.

All the best, we will know shortly.